Login to Your Account


Clinic Roundup


Thursday, August 2, 2012
• InSite Vision Inc., of Alameda, Calif., said it started enrollment in the first Phase III trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

NORTH AMERICA
Tel: +1-215-278-8411
Outside of the US
Tel. +44-20-3811-5317
 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2017 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics